BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 25952784)

  • 21. Biomarkers for personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New advances in genitourinary cancer: evidence gathered in 2014.
    Suárez C; Puente J; Gallardo E; Méndez-Vidal MJ; Climent MA; León L; Olmos D; García del Muro X; González-Billalabeitia E; Grande E; Bellmunt J; Mellado B; Maroto P; González del Alba A
    Cancer Metastasis Rev; 2015 Sep; 34(3):443-64. PubMed ID: 26227584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience.
    Knepper TC; Bell GC; Hicks JK; Padron E; Teer JK; Vo TT; Gillis NK; Mason NT; McLeod HL; Walko CM
    Oncologist; 2017 Feb; 22(2):144-151. PubMed ID: 28179575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An overview of the NCI precision medicine trials-NCI MATCH and MPACT.
    Do K; O'Sullivan Coyne G; Chen AP
    Chin Clin Oncol; 2015 Sep; 4(3):31. PubMed ID: 26408298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Molecular-Genetic Diagnosis and Molecular-Targeted Therapy in Cancer: Challenges in the Era of Precision Medicine].
    Miyachi H
    Rinsho Byori; 2015 Oct; 63(10):1188-93. PubMed ID: 26897855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biologic tools to personalize treatment in genitourinary cancers.
    Bracarda S; Sisani M; Del Buono S; Ishiwa O; Montagnani F;
    Crit Rev Oncol Hematol; 2012 Dec; 84 Suppl 1():e42-8. PubMed ID: 21232974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adaptive Immunity in Genitourinary Cancers.
    Koti M; Bivalacqua T; Black PC; Cathomen T; Galsky MD; Gulley JL; Ingersoll MA; Kamat AM; Kassouf W; Siemens DR; Gao J
    Eur Urol Oncol; 2023 Jun; 6(3):263-272. PubMed ID: 37069029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy.
    Cimadamore A; Scarpelli M; Santoni M; Massari F; Tartari F; Cerqueti R; Lopez-Beltran A; Cheng L; Montironi R
    Curr Drug Metab; 2019; 20(4):305-312. PubMed ID: 30799789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic Sequencing Should Not be Part of the Standard of Care for Most Urologic Cancers.
    Abern MR; Dudinec JV; Inman BA
    Eur Urol Focus; 2022 May; 8(3):639-640. PubMed ID: 35537938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pediatric genitourinary tumors.
    Buckley KS
    Curr Opin Oncol; 2011 May; 23(3):297-302. PubMed ID: 21460723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate cancer molecular profiling: the Achilles heel for the implementation of precision medicine.
    Oliveira-Barros EG; Nicolau-Neto P; Da Costa NM; Pinto LFR; Palumbo A; Nasciutti LE
    Cell Biol Int; 2017 Nov; 41(11):1239-1245. PubMed ID: 28477422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pediatric genitourinary tumors.
    McLean TW; Buckley KS
    Curr Opin Oncol; 2010 May; 22(3):268-73. PubMed ID: 20168230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pediatric genitourinary tumors.
    Herz D; McLellan D; Garrels K; Merguerian PA
    Curr Opin Oncol; 2000 May; 12(3):273-81. PubMed ID: 10841201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives.
    Zhou L; Wang K; Li Q; Nice EC; Zhang H; Huang C
    Expert Rev Proteomics; 2016; 13(4):367-81. PubMed ID: 26923776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Syndromes that Link the Endocrine System and Genitourinary Tract.
    Özlük Y; Kılıçaslan I
    Turk Patoloji Derg; 2015; 31 Suppl 1():155-71. PubMed ID: 26177325
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Personalized Cardiovascular Medicine Today: A Food and Drug Administration/Center for Drug Evaluation and Research Perspective.
    Blaus A; Madabushi R; Pacanowski M; Rose M; Schuck RN; Stockbridge N; Temple R; Unger EF
    Circulation; 2015 Oct; 132(15):1425-32. PubMed ID: 26459078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging Bladder Cancer Biomarkers and Targets of Therapy.
    Netto GJ; Tafe LJ
    Urol Clin North Am; 2016 Feb; 43(1):63-76. PubMed ID: 26614029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The emerging role of circulating tumor cell detection in genitourinary cancer.
    Small AC; Gong Y; Oh WK; Hall SJ; van Rijn CJ; Galsky MD
    J Urol; 2012 Jul; 188(1):21-6. PubMed ID: 22578722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathways to personalized medicine for breast and prostate cancers: emerging diagnostic methods and prognostic biomarkers.
    Watson AP; Egland KA
    S D Med; 2010 Jul; 63(7):247-53. PubMed ID: 20666024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.